De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Epigral Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Epigral heeft een totaal eigen vermogen van ₹12.5B en een totale schuld van ₹9.6B, wat de schuld-eigenvermogensverhouding op 76.9% brengt. De totale activa en totale passiva bedragen respectievelijk ₹27.9B en ₹15.4B. De EBIT Epigral is ₹4.4B waardoor de rentedekking 6.3 is. Het heeft contanten en kortetermijnbeleggingen van ₹31.8M.

Belangrijke informatie

76.9%

Verhouding schuld/eigen vermogen

₹9.64b

Schuld

Rente dekkingsratio	6.3x
Contant	₹31.83m
Aandelen	₹12.54b
Totaal verplichtingen	₹15.40b
Totaal activa	₹27.94b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Jul 04

Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Nov 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹5.0B ) van EPIGRAL } dekken niet de korte termijn passiva ( ₹7.8B ).

Langlopende schulden: De kortetermijnactiva van EPIGRAL ( ₹5.0B ) dekken de langetermijnschulden ( ₹7.6B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 76.6% ) EPIGRAL wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van EPIGRAL is de afgelopen 5 jaar gedaald van 82.3% naar 76.9%.

Schuldendekking: De schuld van EPIGRAL wordt goed gedekt door de operationele kasstroom ( 41.2% ).

Rentedekking: De rentebetalingen op de schuld van EPIGRAL worden goed gedekt door EBIT ( 6.3 x dekking).

Epigral Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024)

Investor sentiment improves as stock rises 15%

Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023)

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023)

Epigral Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump

Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024

Investor sentiment improves as stock rises 22%

Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward

Investor sentiment improves as stock rises 23%

Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023)

Now 23% overvalued after recent price rise

Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024

Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023)

Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023

First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023)

Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023

Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023

Upcoming dividend of ₹2.50 per share at 0.5% yield

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong

Investor sentiment improves as stock rises 15%

Chairman & MD recently bought ₹4.8m worth of stock

Chairman & MD recently bought ₹2.9m worth of stock

Insider recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022)

Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023

Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023

Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022)

With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022)

Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022

Investor sentiment improved over the past week

Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Investor sentiment improved over the past week

Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022

Investor sentiment improved over the past week

CEO, MD & Director recently bought ₹799k worth of stock

Insider recently bought ₹762k worth of stock

Investor sentiment improved over the past week

Insider recently bought ₹8.3m worth of stock

Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Investor sentiment improved over the past week

No independent directors

No independent directors

No independent directors

CEO, MD & Director recently bought ₹5.0m worth of stock

No independent directors

No independent directors

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven